|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab显示文摘AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.METHODS:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases.Secondary endpoints included progression-free survival,chemotherapy duration,and overall survival.Time-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.RESULTS:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal disease.There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts.Of the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone arm.In the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone arm.In a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal perforations was 9/369(2.4%) in the chemotherapy/bevacizumab group and 5/177(2.8%) in the chemotherapy alone group.The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts:MAX 6.9 m vs 4.9 m,HR = 0.64(95%CI:0.42-1.02);P = 0.063;TRACC 9.1 m vs 5.5 m,HR = 0.61(95%CI:0.37-0.86);P = 0.009;NSWCC 8.7 m vs 6.8 m,HR = 0.75(95%CI:0.43-1.32);P = 0.32.Chemotherapy duration was similar across the groups.CONCLUSION:Patients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone. | Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill | 2015 | World Journal of Gastroenterology2015，21，17： | 3 |
| 2 | Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial显示文摘 | Eric Van Cutsem Sanne de Haas Yoon-Koo Kang Atsushi Ohtsu Niall C. Tebbutt Jian Ming Xu Wei Peng Yong Bernd Langer Paul Delmar Stefan J. Scherer Manish A. Shah | 2012 | Journal of Clinical Oncology2012，，17： | 3 |
| 3 | A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy显示文摘 | Gy?rgy Bodoky Constanta Timcheva David Spigel Phillip Stella Tudor Ciuleanu G. Pover N. Tebbutt | 2012 | Investigational New Drugs2012，，3： | 2 |
| 4 | Strategies for overcoming inherent and acquires resist- ance to EGFR inhihitors by targeting downstream effectors in the RAS/PI3K pathway显示文摘 | WEICKHARDT A J TEBBUTT N C MARIADASON J M | 2010 | Current Cancer Drug Targets2010，10，8： | 1 |
| 5 | Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus显示文摘 | Davey RA Tebbutt NC Favaloro JM | 2006 | Lipids Health Dis2006，5，： | 1 |
| 6 | Ultrasonic wave propagation in col oid suspensions andemulsions:recent experimental results显示文摘 | Austin J C Holmes A K Tebbutt J S | | 0，，： | 1 |
| 7 | Therapeutic targeting of the epidermal growth factor receptor in human cancer 显示文摘 | Dhomen NS Mariadason J Tebbutt N | 2012 | Crit Rev Oncog2012，17，1： | 1 |
| 8 | Towards the biomarker - guided rational use of antiangiogenie agents in the treatment of metastatic color- ectal cancer 显示文摘 | Halford MM Tebbutt NC Desai J | 2012 | Colorectal Cancer2012，1，2： | 1 |
| 9 | ATFAX: Randomised Phase II study evaluating weekly docetaxel- based chemotherapy combinations in advanced oesophagogastric cancer: final results of an AGITG trial显示文摘 | Tebbutt N Soumina T Strickland A | 2007 | J Clin Oncol2007，25，18： | 1 |
| 10 | Randomized, muhicenter phase Ⅲ study comparing capecitabine with fluorouracil and oxaliphain with cisplatin in patients with advanced oesophago - gastric cancers:Interim analysis显示文摘 | Tebbutt NC | 2002 | Proc Am Soc Cli Oncol2002，21，： | 1 |
| 11 | Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus 显示文摘 | Davey RA Tebbutt NC | 2006 | Lipids Health Dis2006，5，： | 1 |
| 12 | A phase Ⅰ clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors显示文摘 | Scott AM Tebbutt N Herbertson R | 2007 | Proc Natl Acad Sci2007，104，： | 1 |
| 13 | Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases显示文摘 | Tebbutt NC Norman AR Cunningham D | | 0，，04： | 1 |
| 14 | Significance of COD, BOD and TOC correlations in kinetic models of biological oxidation 显示文摘 | AZIZ J A TEBBUTT T H Y | 1980 | Water Research1980，14，4： | 1 |
| 15 | Strate-gies for overcoming inherent and acquired resistance to EGFR in-hibitors by targeting downstream effectors in the RAS/PI3K path-way 显示文摘 | WEICKHARDT AJ TEBBUTT NC MARIADASON JM | 2010 | Curr Cancer Drug Tar2010，10，8： | 1 |
| 16 | Systemic treatment of colorectal cancer显示文摘 | N.C Tebbutt E Cattell R Midgley D Cunningham D Kerr | 2002 | European Journal of Cancer2002，，7： | 1 |
| 17 | Towards the biomarker-guided rational use of antiangiogenic agents in the treatment of metastatic colorectal cancer显示文摘 | HALFORD MM TEBBUTT NC DESAI J | 2012 | Colorectal Cancer2012，1，2： | 1 |
| 18 | Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:a biomarker evaluation from the AVAGAST randomized phase Ⅲ trial显示文摘 | Van Cutsem E de Haas S Kang Y K Ohtsu A Tebbutt N C Ming Xu J | 2012 | J Clin Oncol2012，30，： | 1 |
| 19 | Randomised, non- compartive Phase II study of weekly docetaxel with eisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AG1TG TTAX trial显示文摘 | Tebbutt NC Cummins MM Sourjina T | 2010 | Br J Cancer2010，102，： | 1 |
| 20 | Intralipidprolongs survival in a rat model of verapamil toxicity显示文摘 | Tebbutt S Harvey M Nicholson T | 2006 | Acad Emerg Med2006，13，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员